Featured Stories
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
Takeda Closes In On Shire With Revised £49/Share Offer
Takeda further ups its offer for Shire to around £49 per share, which Shire’s board has said it is willing to recommend to shareholders, although any final deal remains subject to conditions and Takeda investors appear concerned over the size of the deal.
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.
Latest News
Recent Tweets from Scrip
Polyglucoferron: A New Benchmark For IV Iron Treatment
Iron4u, a pharmaceutical company founded in 2012 by investors from five European countries and based just outside Copenhagen, Denmark, have developed an innovative high-dose IV iron product for the treatment of iron deficiency or iron-deficiency anemia. They believe Polyglucoferron could set a new benchmark in the field of intravenous iron therapy. Developed in partnership with the German company Serumwerk Bernburg, the product is now in Phase III clinical trials for human use as an injection or infusion.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch
Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.
Lilly Rides To Solid First Quarter On Diabetes, Newer Products
Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Circassia Puts Aside R&D, Aims To Grow Commercial Platform
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
TRPharm Chair: 'Dr Reddy's Partnership Is Key To International Expansion'
Turkey's TRPharm, in partnership with India's Dr Reddy's, has become the first company to gain a license for a biosimilar product in Turkey. Chairman Mehmet Göker spoke to Scrip about the company's international expansion plans.
Spotlight On Israel: Compugen Comes Forth
Compugen, a predictive drug discovery and development company, plays an important role within Israel's biopharma sector as one of the oldest businesses in an immature market. Building on its 25-year history, the company is about to embark on a new challenge: clinical development.
Oncology Venture Differentiates Using Big Data Systems Biology
With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
Kaesong Complex A Starting Point For Two Koreas' Healthcare Cooperation?
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.
China Vs Cancer: An Infographic Snapshot
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs from May.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.
QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.
Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche
Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid tumultuous leadership transitions, but his tenure was marked by hits and misses.
Glenmark Eyes Blockbuster Status For First In-House Biologic
Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.